Worldwide virus cases top 20 million, doubling in six weeks

Health staffers of the city government get ready to carry out Covid-19 testing at a park in the Doctores neighborhood in Mexico City on August 11, 2020. (AFP)
Short Url
Updated 11 August 2020

Worldwide virus cases top 20 million, doubling in six weeks

  • The worldwide count of known COVID-19 infections climbed past 20 million on Monday

It took six months for the world to reach 10 million confirmed cases of the coronavirus. It took just over six weeks for that number to double.
The worldwide count of known COVID-19 infections climbed past 20 million on Monday, with more than half of them from just three countries: the US, India and Brazil, according to the tally kept by Johns Hopkins University.
The average number of new cases per day in the US has declined in recent weeks but is still running high at over 54,000, versus almost 59,000 in India and nearly 44,000 in Brazil.


Arthritis drug trialled as potential treatment for COVID-19

Updated 45 min 2 sec ago

Arthritis drug trialled as potential treatment for COVID-19

  • Dr. Andy Martin: We are conducting this study to see whether otilimab could potentially ease the effect of COVID- 19 on the lungs
  • Dr. Tim Felton: The primary end point of this study is that participants are alive and free of lung failure after 28 days — so this research is potentially life-saving

LONDON: The experimental arthritis drug, otilimab, is being trialled as a potential treatment for COVID-19.

The first patient, administered with the drug, is currently being cared for at Manchester Royal Infirmary (MRI), part of Manchester University NHS Foundation Trust (MFT).

The OSCAR study (Otilimab in Severe COVID-19 Related Disease) is sponsored and funded by the pharmaceutical company GlaxoSmithKline.

The study at the MRI is being led by Dr. Andy Martin, an Intensive Care and Anaesthesia Consultant.

Dr. Martin said: “The patients eligible to take part in this study are those experiencing very severe lung difficulties due to COVID-19 infection and are receiving oxygen or ventilator support.

“We are conducting this study to see whether otilimab — which is under investigation as a potential treatment for rheumatoid arthritis — could also potentially ease the effect of coronavirus on the lungs, dampening the impact of the virus on the immune system.

Christopher Corsico, Senior Vice President Development, GSK said: “We are continuing to work hard to find solutions to address the pandemic, including exploring potential treatment options for COVID-19 patients.

“We know that some COVID-19 patients experience an overreaction of their immune system — sometimes referred to as cytokine storm — which can lead to hospitalization or death. We believe that otilimab might be able to help counter or calm this process.

Dr. Tim Felton, Honorary Consultant, Senior Lecturer at The University of Manchester and Clinical Lead for all MFT COVID-19-related research studies, leads OSCAR at Wythenshawe Hospital, which is also part of MFT.

Dr. Felton said: “The primary end point of this study is that participants are alive and free of lung failure after 28 days — so this research is potentially life-saving.

“I’d like to thank our first OSCAR participant — as well as the thousands of others who have taken part in coronavirus studies at MFT to date — as every participant who takes part in our research is contributing to the coordinated effort to enhance understanding of this global pandemic.”